source
- FDA releases FY 2027 user fee rates for prescription, generic, biosimilar, device and over the counter programsThe U.S. Food and Drug Administration has published its user fee schedule for fiscal year 2027. The rates cover prescription drugs, generic drugs, biosimilars, medical devices and over the counter…
- FDA Announces First Participant Selected for TEMPO for Digital Health Devices PilotThe U.S. Food and Drug Administration today announced the first manufacturer selected for the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot.fda press · 8d ago↗ source